Plain-English translation of NCT06546943 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study uses a continuous glucose monitor — a small device that tracks your blood sugar throughout the day — to understand how blood sugar levels change when young people with cystic fibrosis experience a lung infection. Researchers want to see if these blood sugar patterns can help predict how serious the infection is and whether you might need additional antibiotics.
People with cystic fibrosis often develop related blood sugar problems, especially during lung infections. This study aims to find out whether monitoring blood sugar patterns during these infections could help doctors catch complications early and better manage treatment.
You likely qualify if…
You likely don't qualify if…
You would wear a continuous glucose monitor during your lung infection and for a few weeks afterward. You may be part of a baseline visit before the infection (if available), then monitored during the infection itself, and finally checked again about 6 weeks after recovery. You'll also answer brief questions about your breathing problems and symptoms, which helps researchers understand how blood sugar changes relate to how you're feeling.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Sponsor
University of Colorado, Denver
Collaborators
Cystic Fibrosis Foundation, Baylor College of Medicine
Enrollment target
~50 participants
Started
February 2022
Primary completion
April 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
6 Years – 25 Years
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Christine Hovater
University of Colorado, Denver
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.